Erythrocyte: Bacteria Killer and Bacteria Pray
International Journal of Immunology
Volume 3, Issue 1-1, February 2015, Pages: 1-7
Received: Dec. 2, 2014; Accepted: Dec. 20, 2014; Published: Dec. 20, 2014
Views 3863      Downloads 196
Author
Hayk Minasyan, Private Laboratory of Immunology, Yerevan, Armenia
Article Tools
Follow on us
Abstract
Erythrocyte is human blood main bactericidal cell. During movement in blood stream erythrocytes are triboelectrically charged by rubbing to each other and vessel walls and this charge automatically attracts and keeps bacteria on erythrocyte surface. Bacteria fixation on erythrocyte membrane activates the receptors of the membrane and stimulates trans membrane releasing of oxygen from oxyhemoglobin that causes bacteria oxidation and killing. If bacteria survive oxidation and enter erythrocyte they are exposed to higher concentration of oxygen (oxygen reactive species). Very few bacteria survive inside erythrocytes, but some can survive because of lack of oxygen inside erythrocyte and/or bacteria resistance to oxygen reactive species. Killed inside erythrocyte bacteria are released back to plasma and are digested in liver and spleen by local macrophages. Erythrocytes that are injured by bacteria and/or contain killed or living bacteria are destroyed in spleen. Erythrocytes out of bloodstream (in case of hemorrhage, extravasation in lobar pneumonia, etc.) after bacteria engulfment can’t kill bacteria because of lack of oxyhemoglobin and become bacteria container providing both nutrients (protein, iron, carbohydrates, etc.) for bacteria growth and some defense against phagocytes and antibodies. In bloodstream erythrocyte is bacteria killer, out of bloodstream it is bacteria pray.
Keywords
Erythrocyte, Bacteria, Blood, Bacteremia, Sepsis, Liver, Spleen
To cite this article
Hayk Minasyan, Erythrocyte: Bacteria Killer and Bacteria Pray, International Journal of Immunology. Special Issue: Antibacterial Cellular and Humoral Immunity. Vol. 3, No. 1-1, 2015, pp. 1-7. doi: 10.11648/j.iji.2015030101.11
References
[1]
Minasyan H, Erythrocyte and blood antibacterial defense. Eur J Microbiol Immunol. 2014;4(2):138–3.
[2]
Minasyan H, Erythrocyte and Leukocyte: Two Partners in Bacteria Killing. International Reviews of Immunology, 2014, (doi: 10.3109/08830185.2014.956359).
[3]
Marchi SF, Bodenmuller M, Lai D, Seiler C. Pulmonary venous flow velocity patterns in 404 individuals without cardiovascular disease. Heart. 2001; 85(1): 23–9.
[4]
Mason DT, Mills CJ, Schillingford JP, Braunwald E, Measurement of Instantaneous Blood Flow Velocity and Pressure in Conscious Man with a Catheter-Tip Velocity ProbeCirculation.1969;40:603-14.
[5]
Gardin JM, Burn CS, Childs WJ, Henry WL. Evaluation of blood flow velocity in the ascending aorta and main pulmonary artery of normal subjects by Doppler echocardiography. Am Heart J. 1984; Feb;107(2):310-9.
[6]
Dominguez de Villota ED, Ruiz Carmona MT, Rubio JJ, de Andrés S. Equality of the in vivo and in vitro oxygen-binding capacity of haemoglobin in patients with severe respiratory disease. Br J Anaesth .1981; 53 (12): 1325–8.
[7]
Costanzo, LS. Physiology. Hagerstwon, Philadelphia.MD: Lippincott Williams & Wilkins;2007.
[8]
Anthea M, Hopkins J, McLaughlin CW, Johnson S, Warner MQ, LaHart D, Wright JD. Human Biology and Health. Englewood Cliffs, New Jersey, USA: Prentice Hall; 1993.
[9]
Voet, D. Fundamentals of Biochemistry, 3rd. ed., New York: John Wiley & Sons; 2008.
[10]
Gaetani GF, Ferraris AM, Rolfo M, Kirkman HN. Predominant role of catalase in the disposal of hydrogen peroxide within human erythrocytes. Blood. 1996;87:1595–99.
[11]
Masuoka N, Sugiyama H, Ishibashi N, Wang DH, Masuoka T, Kodama H, Nakano T. Characterization of acatalasemic erythrocytes treated with low and high dose hydrogen peroxide: hemolysis and aggregation. J Biol Chem. 2006;281:21728–34.
[12]
Demple B. Regulation of bacterial oxidative stress genes. Annu. Rev. Genet. 1991;25:315–37.
[13]
Imlay JA. Cellular defenses against superoxide and hydrogen peroxide. Annu. Rev. Biochem. 2008;77:755–76.
[14]
Gouet P, Jouve HM, Dideberg O. Crystal structure of Proteus mirabilis PR catalase with and without bound NADPH. J Mol Biol. 1995;249:933–954.
[15]
Hakansson KO, Brugna M, Tasse L. The three-dimensional structure of catalase from Enterococcus faecalis. Acta Crystallogr D. 2004;60:1374–1380.
[16]
Hillar A, Nicholls P, Switala J, Loewen PC. NADPH binding and control of catalase compound II formation: comparison of bovine, yeast, and Escherichia coli enzymes. Biochem J.1994;300:521–39.
[17]
Chelikani P, Fita I, Loewen PC. Diversity of structures and properties among catalases. Cell Mol Life Sci. 2004;61:192–208.
[18]
Whittaker J. W. Non-heme manganese catalase – the ‘other’ catalase. Arch Biochem Biophys. 2012 Sep 15; 525(2): 111–20.
[19]
Beyer WF, Fridovich I. Catalases—with and without heme. Basic Life Sci. 1988;49:651–61.
[20]
Chelikani P, Fita I, Loewen PC. Diversity of structures and properties among catalases.Cell. Mol. Life Sci. 2004 Jan; 61 (2): 192–208.
[21]
La Carbona S, Sauvageot N, Giard JC, Benachour A, Posteraro B, et al. Comparative study of the physiological roles of three peroxidases (NADH peroxidase, Alkyl hydroperoxide reductase and Thiol peroxidase) in oxidative stress response, survival inside macrophages and virulence of Enterococcus faecalis. Mol Microbiol. 2007;66:1148–63.
[22]
Fick A: Ueber die Messung des Blutquantums in den Herzventrikeln. Verh Phys Med Ges Wurzburg. 1870;2:16–28.
[23]
Barratt-Boyes B, Wood E: The oxygen saturation of blood in the venae cavae, right-heart chambers and pulmonary vessels of healthy subjects. J Lab Clin Med. 1957; 50:93–106.
[24]
Hillman RS, Ault KA, Rinder HM. Hematology in Clinical Practice: A Guide to Diagnosis and Management (4 ed.). New York: McGraw-Hill Professional; 2005.
[25]
Pierigè F, Serafini S, Rossi L, Magnani M. Cell-based drug delivery. Advanced Drug Delivery Reviews. 2008;60(2): 286–95.
[26]
Marieb EN, Hoehn K. The Cardiovascular System:Blood Vessels. Human anatomy & physiology, 9th ed. New Jersey: Pearson Education, Inc. 2013 p. 712.
[27]
Chen YM, Lee HC, Chang CM, Chuang YC, Ko WC. Clostridium bacteremia: emphasis on the poor prognosis in cirrhotic patients. J Microbiol Immunol Infect. 2001 Jun;34(2):113-8.
[28]
Gorbach SL. Clostridium perfringens and other clostridia. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious diseases. 2nd ed. Philadelphia: W.B. Saunders; 1998. p. 1925–30.
[29]
Peranio VA, Cross SA, Goldstein EJC. Incidence and clinical significance of anaerobic bacteremia in a community hospital. CID 1993; 16:S288–91.
[30]
Finegold SM. Anaerobic bacteria in human diseases, New York, Academic Press, 1977.
[31]
Felsen J, Wolarsky W. Suppurative pylephlebitis with bacteremia in chronic ulcerative colitis. Ann Intern Med. 1950;33(1):211-16.
[32]
Libby DB, Bearman G. Bacteremia due to Clostridium difficile—review of the literature. Intern J Infect Dis, 2009; Vol.13, Issue 5:305-9.
[33]
Jacobs A, Barnard K, Fishel R, Gradon JD. Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2001;80(2):88–101.
[34]
Wolf LE, Gorbach SL, Granowitz EV. Extraintestinal Clostridium difficile: 10 years’ experience at a tertiary care hospital. Mayo Clin Proc. 1998;73:943–947.
[35]
Garcia-Lechuz JM, Hernangomez S, San Juan R, Pelaez T, Bouza E. Extra-intestinal infections caused by Clostridium difficile. Clin Microbiol Infect. 2001;7(8):453–457.
[36]
Feldman RJ, Kallich M, Weinstein MP. Bacteremia due to Clostridium difficile: case report and review of extraintestinal C. difficile infections. Clin Infect Dis. 1995;20(6):1560–1562.
[37]
Gorbach SL. Clostridium perfringens and other clostridia. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious diseases. 2nd ed. Philadelphia: W.B. Saunders; 1998. p. 1925–30.
[38]
Peranio VA, Cross SA, Goldstein EJC. Incidence and clinical significance of anaerobic bacteremia in a community hospital. CID 1993; 16:S288–91.
[39]
Hallit RR, Afridi M, Sison R, Salem E, Boghossian J, Slim J. Clostridium tetani bacteraemia. J Med Microbiol. 2013 Jan;62(Pt 1):155-6.
[40]
Lockhart PB, Brennan MT, Sasser HC, Fox PC, Paster BJ, Bahrani-Mougeot FK. Bacteremia associated with toothbrushing and dental extraction. Circulation. 2008; 117: 3118-3125.
[41]
Little JW, Falace DA, Miller CS, Rhodus NL. Infective endocarditis. In: Dental management of the medically compromised patient. 6th edition. Toronto: Mosby, Inc.; 2002. p. 21-51.
[42]
Forner L, Larsen T, Kilian M, Holmstrup P. Incidence of bacteremia after chewing, tooth brushing and scaling in individuals with periodontal inflammation. J Clin Periodontol. 2006 Jun;33(6):401-7.
[43]
Hartzell JD, Torres D, Kim P, Wortmann G. Incidence of bacteremia after routine tooth brushing. Am J Med Sci. 2005; 329: 178-180.
[44]
Hall G, Hedstrцm SA, Heimdahl A, Nord CE. Prophylactic administration of penicillins for endocarditis does not reduce the incidence of postextraction bacteremia. Clin Infect Dis.1993; 17: 188-194.
[45]
Lockhart PB, Durack DT. Oral microflora as a cause of endocarditis and other distant site infections. Infect Dis Clin North Am. 1999; 13: 833-50.
[46]
Tomas I, Alvarez M, Limeres J, Potel C, Medina J, Diz P. Prevalence,duration and aetiology of bacteraemia following dental extractions. Oral Dis. 2007 Jan;13(1):56-62.
[47]
Takai S, Kuriyama T, Yanagisawa M, Nakagawa K, Karasawa T. Incidence and bacteriology of bacteremia associated with various oral and maxillofacial surgical procedures. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):292-8.
[48]
Mandal BK, Brennand J. Bacteraemia in salmonellosis: a 15 year retrospective study from a regional infectious diseases unit. BMJ. 1988; 297:1242.
[49]
Preveden T , Knezević K, Brkić S, Jelesić Z. Salmonella bacteremia. Med Pregl. 2001 Jul-Aug;54(7-8):367-70.
[50]
de Jong HK, Parry CM, van der Poll T, Wiersinga WJ. Host-pathogen interaction in invasive Salmonellosis. PLoS Pathog. 2012;8(10):e1002933.
[51]
Tsolis RM, Young GM, Solnick JV, Baumler AJ. From bench to bedside: stealth of enteroinvasive pathogens. Nat Rev Microbiol. 2008;6: 883–92.
[52]
Gruner BM, Han SR, Meyer HG, Wulf U, Bhakdi S, Siegel EK. Characterization of a Catalase-Negative Methicillin-Resistant Staphylococcus aureus strain. J Clin Microbiol. 2007;1:2684–85.
[53]
WE, Bannerman. TL. In: Staphylococcus and Micrococcus. Manual of clinical microbiology. 7th ed. Murray PR, et al., editors. Washington, DC: ASM Press; 1999. p. 264–282.
[54]
Sanz R, Marn I, Ruiz Santa Quiteria JA, Orden JA, Cid D, et al RM Diez. Catalase deficiency in Staphylococcus aureus subsp. anaerobius is associated with natural loss-of-function mutations within the structural gene. Microbiology. 2000;146:465–75.
[55]
Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis. 1987; 9:891.
[56]
Shurland S, Zhan M, Bradham DD, Roghmann MC. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol. 2007; 28:273.
[57]
Luderitz O, Jann K, Wheat R. Somatic and capsular antigens of gram-negative bacteria. Comp Biochem Physiol. 1968;A26:105-28.
[58]
Smith H. Microbial surfaces in relation to pathogenicity. Bacteriol Rev. 1977;41:475-500.
[59]
Timmis KNG, Boulnois J, Bitter-Suermann D, Cabello FC. Surface components of Escherichia coli that mediate resistance to the bactericidal activity of serum and phagocytes. Curr Top Microbiol Immunol. 1985;118:197-18.
[60]
Bortotussi R. Capsular KI polysaccharide of Escherichia coli: relationship to virulence in newborn rats and resistance to phagocytosis. Infect Immun. 1978; 25:293-8.
[61]
Karakawa WW, Vann WF. Capsular polysaccharides of Staphylococcus aureus. Semin Infect Dis. 1982;4:285-3.
[62]
Hochkeppel HK, Brau D, Vischer GW, Sutter U, Staeubli R, Guggenheim EL et al. Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8. J. Clin Microbiol. 1987;25:526-30.
[63]
Lee JC, Liu MJ, Parsonnet J, Arbeit RD. Expression of type-8 capsular polysaccharide and production of toxic shock syndrome toxin-1 are associated among vaginal isolates of Staphylococcus aureus. J Clin Microbiol. 1990;28:2612-15.
[64]
Schmid EN, Menge B, Lickfeld KG. Capsule fine structure in thin slices of Klebsiella pneumoniae. J Ultrastruct Res. 1981;75:41-9.
[65]
Holmes RL, Kozinn WP. Pneumonia and Bacteremia Associated with Haemophilus influenzae Serotype d. J Clin Microbiol. 1983 Sep; 18(3):730–2.
[66]
Laupland KB, Gregson DB, Zygun DA. Severe bloodstream infections: a population-based assessment. Crit Care Med. 2004;32:992-7.
[67]
Spinosa MR, Progida C, Talà A, Cogli L, Alifano P, Bucci C. The Neisseria meningitides: Capsule Is Important for Intracellular Survival in Human Cells. Infect Immun. July 2007; vol. 75 no.7 :3594-3603.
[68]
Morona JKD, Miller C, Morona R, Paton JC. The effect that mutations in the conserved capsular polysaccharide biosynthesis genes cpsA, cpsB, and cpsD have on virulence of Streptococcus pneumoniae. J Infect Dis. 2004;189:1905-13.
[69]
Morona JK, Morona R, Paton JC. Attachment of capsular polysaccharide to the cell wall of Streptococcus pneumoniae type 2 is required for invasive disease. Proc Natl Acad Sci U. S. A. 2006;103:8505-10.
[70]
Vidal F, Mensa J, Almela M. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med. 1996;156:2121.
[71]
Wisplinghoff H, Bischoff T, Tallent SM. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309.
[72]
Hogevik H, Olaison L, Andersson R, Lindberg J, Alestig K. Epidemiologic aspects of infective endocarditis in an urban population. A 5-year prospective study. Medicine (Baltimore). 1995 Nov;74(6):324-39.
[73]
Beck J, Garcia R, Heiss G, Vokonas PS, Offenbacher S. Periodontal disease and cardiovascular disease. J Periodontol. 1996 Oct;67(10 Suppl):1123-37.
[74]
Beck JD, Slade G, Offenbacher S. Oral disease, cardiovascular disease and systemic inflammation. Periodontol. 2000;23:110-20.
[75]
Genco RJ, Wu TJ, Grossi S. Periodontal microflora related to the risk for myocardial infarction: A case control study. J Dent Res. 1999;78:457.
[76]
Clough M. The cultivation of tubercle bacilli from the circulating blood in miliary tuberculosis. Am Rev Tuberculosis. 1917;1: 598 –621.
[77]
Stead W, Bates J. Evidence of a "silent" bacillemia in primary tuberculosis. Ann Intern Med. 1971; 74: 559 –561.
[78]
El Sahly HM, Teeter LD, Musser JM, Graviss EA. Mycobacterium tuberculosis bacteraemia: experience from a non-endemic urban centre. Clin Microbiol Infect. 2014 Mar;20(3):263-8.
[79]
McDonald L, Archibald L, Rheanpumikankit S. et al. Unrecognised Mycobacterium tuberculosis bacteraemia among hospital inpatients in less developed countries. Lancet. 1999; 354: 1159 –63.
[80]
Jackett P S, Aber V R, Lowrie D B. Virulence and resistance to superoxide, low pH and hydrogen peroxide among strains of Mycobacterium tuberculosis. J Gen Microbiol. 1978;104:37–45.
[81]
Mitchison D A, Selkon J B, Lloyd J. Virulence in the guinea-pig, susceptibility to hydrogen peroxide, and catalase activity of isoniazid-sensitive tubercle bacilli from South Indian and British patients. J Pathol Bacteriol. 1963;86:377–86.
[82]
Heym B, Zhang Y, Poulet S, Young D, Cole S T. Characterization of the katG gene encoding a catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis. J Bacteriol. 1993;175:4255–59.
[83]
Drutz DJ, Chen TSN, Lu WH. The continuous bacteremia of lepromatous leprosy. N Engl J Med. 1972; 287: 159-64.
[84]
Sengupta U, Ramu G, Desikan KV. Evaluation of bacteremia in leprosy patients. Lepr India. 1978; 50: 381-7.
[85]
Padma MN, Desikan KV. Bacillaemia in leprosy. Indian J Med Res. 1975; 63: 888-92.
[86]
Beveridge TJ. Mechanism of Gram variability in select bacteria. J Bacteriol. 1990;172:1609–1620.
[87]
Brock T D, Madigan M T, Martinko J M, Parker J. Biology of microorganisms. 7th ed. Englewood Cliffs, N.J: Prentice-Hall International, Inc.; 1994.
[88]
Davies J A, Anderson G K, Beveridge T J, Clark H C. Chemical mechanism of the Gram stain and synthesis of a new electron-opaque marker for electron microscopy which replaces the iodine mordant of the stain. J Bacteriol.1983;156:837–845.
[89]
Ratledge C, Dover LG. Iron metabolism in pathogenic bacteria. Annu Rev Microbiol. 2000;54: 881–941.
[90]
Andrews SC, Robinson AK, Rodriguez-Quinones F. Bacterial iron homeostasis. FEMS Microbiol Rev. 2003;27:215–37.
[91]
Bullen JJ, Rogers HJ, Spalding PB, Ward CG. Iron and infection: the heart of the matter. FEMS Immunol Med Microbiol. 2005;43: 325–30.
[92]
Biozzi G, Stiffel C. The physiopathology of the reticuloendothelial cells of the liver and the spleen. In: Popper, H. and Shaffner, F. (Eds): Progress in liver diseases. New York: Grune & Stratton;1965. p.166-9.
[93]
Biozzi G, Benacerraf B, Halpern BN. Quantitative study of the granulopoetic activity of the reticuloendothelial system II. A study of the kinetics of the granulopoetic activity of the RES in relation to the dose of carbon injected. Relationship between the weight of the organs and their activity. Br J Exp Pathol.1953; 34: 441-8.
[94]
Wanless IR. Physioanatomic considerations. In: Schiff, E.R., Sorrell, M.F., Maddrey, W.C. (Eds.), Schiff’s Diseases of the Liver. Philadelphia: Lippincott-Raven; 1999.p. 3–38.
[95]
Mebius RE, Kraal G, Structure and function of the spleen. Nature Reviews Immunology. 2005 August;5: 606-16.
[96]
Bowdler A: The Complete Spleen: Structure, Function and Clinical Disorders.2nd edition. New Jersey: Humana Press; 2002.
[97]
Pierigè F, Serafini S, Rossi L, Magnani M . Cell-based drug delivery. Advanced Drug Delivery Reviews. 2008 January; 60 (2): 286–95.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186